Clinical and laboratory data in patients with multiple myeloma with and without 13q14 deletion
Variable* . | 13q14 Deleted (n = 46) . | Normal 13q14 (n = 51) . | P Value . |
---|---|---|---|
Age, y | 65.3 | 65.2 | .95 |
Sex, % male/% female | 35.6/64.4 | 35.8/64.2 | .97 |
Stage of MM at diagnosis, % of patients | |||
I or II | 27.1 | 49.1 | |
III | 72.9 | 50.9 | .022 |
Paraprotein, % of patients | |||
IgA | 22.9 | 27.3 | |
Non-IgA | 77.1 | 72.7 | .62 |
Percentage of bone marrow plasma cells | 37 | 29 | .085 |
Intermediate and high-grade morphologic features, % of patients | 29.6 | 15.7 | .10 |
Creatinine (μmol/L) | 136 | 111 | .18 |
Hemoglobin (g/L) | 104 | 113 | .10 |
Platelets (×109/L) | 183 | 204 | .26 |
β2-Microglobulin (mg/L) | 6.7 | 3.6 | .059 |
C-reactive protein (mg/L) | 30 | 16 | .27 |
Lactate dehydrogenase (U/L) | 203 | 181 | .27 |
Deletion of 17p13, % of patients | 38.6 | 11.5 | .002 |
Ki-67, % of positive cells† | 22.0 | 15.6 | .0008 |
Response to induction chemotherapy, % of patients‡ | 40.8 | 78.6 | .009 |
Variable* . | 13q14 Deleted (n = 46) . | Normal 13q14 (n = 51) . | P Value . |
---|---|---|---|
Age, y | 65.3 | 65.2 | .95 |
Sex, % male/% female | 35.6/64.4 | 35.8/64.2 | .97 |
Stage of MM at diagnosis, % of patients | |||
I or II | 27.1 | 49.1 | |
III | 72.9 | 50.9 | .022 |
Paraprotein, % of patients | |||
IgA | 22.9 | 27.3 | |
Non-IgA | 77.1 | 72.7 | .62 |
Percentage of bone marrow plasma cells | 37 | 29 | .085 |
Intermediate and high-grade morphologic features, % of patients | 29.6 | 15.7 | .10 |
Creatinine (μmol/L) | 136 | 111 | .18 |
Hemoglobin (g/L) | 104 | 113 | .10 |
Platelets (×109/L) | 183 | 204 | .26 |
β2-Microglobulin (mg/L) | 6.7 | 3.6 | .059 |
C-reactive protein (mg/L) | 30 | 16 | .27 |
Lactate dehydrogenase (U/L) | 203 | 181 | .27 |
Deletion of 17p13, % of patients | 38.6 | 11.5 | .002 |
Ki-67, % of positive cells† | 22.0 | 15.6 | .0008 |
Response to induction chemotherapy, % of patients‡ | 40.8 | 78.6 | .009 |